Sphingolipid therapy in myocardial ischemia-reperfusion injury

Biochimica et Biophysica Acta - General Subjects

Volumn 1780, Issue 3, 2008, Pages 571-576

  Gundewar, Susheel ^a   Lefer, David J ^a  

^a Cardiology Division   (United States)

Author keywords

db db; Diabetes; Myocardial infarction; N,N,N trimethylsphingosine; ob ob; Obesity

Indexed keywords

CERAMIDE; LIVER ENZYME; N,N,N TRIMETHYLSPHINGOSINE CHLORIDE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE; SULFATIDE; UNCLASSIFIED DRUG;

CELL PROTECTION; DIABETES MELLITUS; DRUG MECHANISM; ENZYME BLOOD LEVEL; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; LIVER ISCHEMIA; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; WILD TYPE;

ANIMALS; MYOCARDIAL REPERFUSION INJURY; SPHINGOLIPIDS; SPHINGOSINE;

ANIMALIA; MURINAE; MUS;

EID: 40749135742     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.08.014     Document Type: Review

References (72)

1. Murray C.J., and Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349 (1997) 1436-1442
2. Thom T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., Manolio T., Zheng Z.J., Flegal K., O'Donnell C., Kittner S., Lloyd-Jones D., Goff Jr. D.C., Hong Y., Adams R., Friday G., Furie K., Gorelick P., Kissela B., Marler J., Meigs J., Roger V., Sidney S., Sorlie P., Steinberger J., Wasserthiel-Smoller S., Wilson M., and Wolf P. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
3. Braunwald E., and Kloner R.A. Myocardial reperfusion: a double-edged sword?. J. Clin. Invest. 76 (1985) 1713-1719
4. McCord J.M. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 312 (1985) 159-163
5. Nayler W.G. The role of calcium in the ischemic myocardium. Am. J. Pathol. 102 (1981) 262-270
6. Shen A.C., and Jennings R.B. Myocardial calcium and magnesium in acute ischemic injury. Am. J. Pathol. 67 (1972) 417-440
7. Lefer A.M., and Lefer D.J. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc. Res. 32 (1996) 743-751
8. Entman M.L., Michael L., Rossen R.D., Dreyer W.J., Anderson D.C., Taylor A.A., and Smith C.W. Inflammation in the course of early myocardial ischemia. FASEB J. 5 (1991) 2529-2537
9. Welbourn C.R., Goldman G., Paterson I.S., Valeri C.R., Shepro D., and Hechtman H.B. Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil. Br. J. Surg. 78 (1991) 651-655
10. Reffelmann T., and Kloner R.A. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res. Cardiol. 101 (2006) 359-372
11. Eefting F., Rensing B., Wigman J., Pannekoek W.J., Liu W.M., Cramer M.J., Lips D.J., and Doevendans P.A. Role of apoptosis in reperfusion injury. Cardiovasc. Res. 61 (2004) 414-426
12. Umansky S.R., Cuenco G.M., Khutzian S.S., Barr P.J., and Tomei L.D. Post-ischemic apoptotic death of rat neonatal cardiomyocytes. Cell Death Differ. 2 (1995) 235-241
13. Fliss H., and Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ. Res. 79 (1996) 949-956
14. Maggio B., Fanani M.L., Rosetti C.M., and Wilke N. Biophysics of sphingolipids II. Glycosphingolipids: an assortment of multiple structural information transducers at the membrane surface. Biochim. Biophys. Acta 1758 (2006) 1922-1944
15. Futerman A.H. Intracellular trafficking of sphingolipids: relationship to biosynthesis. Biochim. Biophys. Acta 1758 (2006) 1885-1892
16. Hannun Y.A., and Bell R.M. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 243 (1989) 500-507
17. Ohanian J., and Ohanian V. Sphingolipids in mammalian cell signalling. Cell Mol. Life Sci. 58 (2001) 2053-2068
18. Levade T., Auge N., Veldman R.J., Cuvillier O., Negre-Salvayre A., and Salvayre R. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ. Res. 89 (2001) 957-968
19. Skaper S.D., Leon A., and Toffano G. Ganglioside function in the development and repair of the nervous system. From basic science to clinical application. Mol. Neurobiol. 3 (1989) 173-199
20. Sonnino S., Mauri L., Chigorno V., and Prinetti A. Gangliosides as components of lipid membrane domains. Glycobiology 17 (2007) 1R-13R
21. Ferrari G., Anderson B.L., Stephens R.M., Kaplan D.R., and Greene L.A. Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J. Biol. Chem. 270 (1995) 3074-3080
22. Karliner J.S., Honbo N., Summers K., Gray M.O., and Goetzl E.J. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J. Mol. Cell Cardiol. 33 (2001) 1713-1717
23. Maulik N., Das D.K., Gogineni M., Cordis G.A., Avrova N., and Denisova N. Reduction of myocardial ischemic reperfusion injury by sialylated glycosphingolipids, gangliosides. J. Cardiovasc. Pharmacol. 22 (1993) 74-81
24. Jin Z.Q., Zhou H.Z., Zhu P., Honbo N., Mochly-Rosen D., Messing R.O., Goetzl E.J., Karliner J.S., and Gray M.O. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H1970-H1977
25. Ishizuka I. Chemistry and functional distribution of sulfoglycolipids. Prog. Lipid. Res. 36 (1997) 245-319
26. Merten M., and Thiagarajan P. Role for sulfatides in platelet aggregation. Circulation 104 (2001) 2955-2960
27. Lefer A.M. Role of selectins in myocardial ischemia-reperfusion injury. Ann. Thorac. Surg. 60 (1995) 773-777
28. Yamada K., Tojo S.J., Hayashi M., and Morooka S. The role of P-selectin, sialyl Lewis X and sulfatide in myocardial ischemia and reperfusion injury. Eur. J. Pharmacol. 346 (1998) 217-225
29. Won J.S., and Singh I. Sphingolipid signaling and redox regulation. Free Radic. Biol. Med. 40 (2006) 1875-1888
30. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest. 110 (2002) 3-8
31. Kolesnick R., and Golde D.W. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77 (1994) 325-328
32. Hannun Y.A., and Obeid L.M. Ceramide: an intracellular signal for apoptosis. Trends Biochem. Sci. 20 (1995) 73-77
33. Spiegel S., Foster D., and Kolesnick R. Signal transduction through lipid second messengers. Curr. Opin. Cell Biol. 8 (1996) 159-167
34. Spiegel S., and Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J. Biol. Chem. 277 (2002) 25851-25854
35. Dbaibo G.S., Obeid L.M., and Hannun Y.A. Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa. B. J. Biol. Chem. 268 (1993) 17762-17766
36. Cifone M.G., De Maria R., Roncaioli P., Rippo M.R., Azuma M., Lanier L.L., Santoni A., and Testi R. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J. Exp. Med. 180 (1994) 1547-1552
37. Bielawska A.E., Shapiro J.P., Jiang L., Melkonyan H.S., Piot C., Wolfe C.L., Tomei L.D., Hannun Y.A., and Umansky S.R. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am. J. Pathol. 151 (1997) 1257-1263
38. Hannun Y.A., Loomis C.R., Merrill Jr. A.H., and Bell R.M. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem. 261 (1986) 12604-12609
39. Hung W.C., Chang H.C., and Chuang L.Y. Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells. Biochem. J. 338 Pt 1 (1999) 161-166
40. Jin Z.Q., Goetzl E.J., and Karliner J.S. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 110 (2004) 1980-1989
41. Theilmeier G., Schmidt C., Herrmann J., Keul P., Schafers M., Herrgott I., Mersmann J., Larmann J., Hermann S., Stypmann J., Schober O., Hildebrand R., Schulz R., Heusch G., Haude M., von Wnuck Lipinski K., Herzog C., Schmitz M., Erbel R., Chun J., and Levkau B. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114 (2006) 1403-1409
42. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., and Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381 (1996) 800-803
43. Endo K., Igarashi Y., Nisar M., Zhou Q.H., and Hakomori S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res. 51 (1991) 1613-1618
44. Igarashi Y., and Hakomori S. Enzymatic synthesis of N,N-dimethyl-sphingosine: demonstration of the sphingosine: N-methyltransferase in mouse brain. Biochem. Biophys. Res. Commun. 164 (1989) 1411-1416
45. Igarashi Y., Kitamura K., Toyokuni T., Dean B., Fenderson B., Ogawass T., and Hakomori S. A specific enhancing effect of N,N-dimethylsphingosine on epidermal growth factor receptor autophosphorylation. Demonstration of its endogenous occurrence (and the virtual absence of unsubstituted sphingosine) in human epidermoid carcinoma A431 cells. J. Biol. Chem. 265 (1990) 5385-5389
46. Jin Z.Q., and Karliner J.S. Low dose N,N-dimethylsphingosine is cardioprotective and activates cytosolic sphingosine kinase by a PKCepsilon dependent mechanism. Cardiovasc. Res. 71 (2006) 725-734
47. Igarashi Y., Hakomori S., Toyokuni T., Dean B., Fujita S., Sugimoto M., Ogawa T., el-Ghendy K., and Racker E. Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. Biochemistry 28 (1989) 6796-6800
48. Ping P., Zhang J., Zheng Y.T., Li R.C., Dawn B., Tang X.L., Takano H., Balafanova Z., and Bolli R. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. Circ. Res. 85 (1999) 542-550
49. Kimura S., Kawa S., Ruan F., Nisar M., Sadahira Y., Hakomori S., and Igarashi Y. Effect of sphingosine and its N-methyl derivatives on oxidative burst, phagokinetic activity, and trans-endothelial migration of human neutrophils. Biochem. Pharmacol. 44 (1992) 1585-1595
50. Okoshi H., Hakomori S., Nisar M., Zhou Q.H., Kimura S., Tashiro K., and Igarashi Y. Cell membrane signaling as target in cancer therapy: II. Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation. Cancer Res. 51 (1991) 6019-6024
51. Murohara T., Buerke M., Margiotta J., Ruan F., Igarashi Y., Hakomori S., and Lefer A.M. Myocardial and endothelial protection by TMS in ischemia-reperfusion injury. Am. J. Physiol. 269 (1995) H504-H514
52. Campbell B., Shin Y.K., Scalia R., and Lefer A.M. Beneficial effects of N,N,N-trimethylsphingosine following ischemia and reperfusion in the isolated perfused rat heart. Cardiovasc. Res. 39 (1998) 393-400
53. Scalia R., Murohara T., Delyani J.A., Nossuli T.O., and Lefer A.M. Myocardial protection by N,N,N-trimethylsphingosine in ischemia reperfusion injury is mediated by inhibition of P-selectin. J. Leukoc. Biol. 59 (1996) 317-324
54. Murohara T., Scalia R., and Lefer A.M. Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ. Res. 78 (1996) 780-789
55. Cataisson C., Pearson A.J., Torgerson S., Nedospasov S.A., and Yuspa S.H. Protein kinase C alpha-mediated chemotaxis of neutrophils requires NF-kappa B activity but is independent of TNF alpha signaling in mouse skin in vivo. J. Immunol. 174 (2005) 1686-1692
56. Shattil S.J., Kashiwagi H., and Pampori N. Integrin signaling: the platelet paradigm. Blood 91 (1998) 2645-2657
57. Hers I., Donath J., van Willigen G., and Akkerman J.W. Differential involvement of tyrosine and serine/threonine kinases in platelet integrin alphaIIbbeta3 exposure. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 404-414
58. Watson S.P., McNally J., Shipman L.J., and Godfrey P.P. The action of the protein kinase C inhibitor, staurosporine, on human platelets. Evidence against a regulatory role for protein kinase C in the formation of inositol trisphosphate by thrombin. Biochem. J. 249 (1988) 345-350
59. van Willigen G., and Akkerman J.W. Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIB-IIIA complex of human platelets. Biochem. J. 273 Pt 1 (1991) 115-120
60. van Willigen G., and Akkerman J.W. Regulation of glycoprotein IIB/IIIA exposure on platelets stimulated with alpha-thrombin. Blood 79 (1992) 82-90
61. Jones S.P., Girod W.G., Granger D.N., Palazzo A.J., and Lefer D.J. Reperfusion injury is not affected by blockade of P-selectin in the diabetic mouse heart. Am. J. Physiol. 277 (1999) H763-H769
62. Schmitz-Peiffer C. Signalling aspects of insulin resistance in skeletal muscle: mechanisms induced by lipid oversupply. Cell. Signal. 12 (2000) 583-594
63. Schmidt A.M., Yan S.D., Wautier J.L., and Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84 (1999) 489-497
64. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
65. Lin L. RAGE on the Toll road?. Cell Mol. Immunol. 3 (2006) 351-358
66. Wautier J.L., and Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 95 (2004) 233-238
67. Inoguchi T., Battan R., Handler E., Sportsman J.R., Heath W., and King G.L. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 11059-11063
68. Garris D.R. Morphometric analysis of obesity (ob/ob)- and diabetes (db/db)-associated hypothalamic neuronal degeneration in C57BL/KsJ mice. Brain Res. 501 (1989) 162-170
69. Sahai A., Malladi P., Pan X., Paul R., Melin-Aldana H., Green R.M., and Whitington P.F. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol.: Gasterointest. Liver Physiol. 287 (2004) G1035-G1043
70. da Costa K.A., Cochary E.F., Blusztajn J.K., Garner S.C., and Zeisel S.H. Accumulation of 1,2-sn-diradylglycerol with increased membrane-associated protein kinase C may be the mechanism for spontaneous hepatocarcinogenesis in choline-deficient rats. J. Biol. Chem. 268 (1993) 2100-2105
71. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., and Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
72. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn A.A., Karlsson G., and Radue E.W. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355 (2006) 1124-1140